Technology | Breast Imaging | November 28, 2016

Dilon Diagnostics and GE Healthcare Announce FDA Clearance of Discovery NM750b Breast Biopsy Accessory

Localization device designed to accurately locate breast lesions in 3-D using information from stereotactic pairs of 2-D images

Dilon Diagnostics, GE Healthcare, RSNA 2016, Discovery NM750b molecular breast imaging system, biopsy accessory, FDA clearance

November 28, 2016 — Dilon Diagnostics and GE Healthcare announced the U.S. Food and Drug Administration (FDA) clearance of the Molecular Breast Imaging (MBI) localization accessory for breast biopsy. The Discovery NM750b and the breast biopsy accessory will be presented at the 2016 Radiological Society of North America (RSNA) conference, Nov. 27-Dec. 1 in Chicago. The Discovery NM750b will be at the Dilon booth number 6132.

The approval comes shortly after Dilon and GE signed an exclusive agreement for Dilon to distribute GE's Discovery NM750b Molecular Breast Imaging system in North America.

The Discovery NM 750b breast imaging system, designed to measure and image the distribution of selected single photon emission radioisotopes in the human body to aid in the evaluation of lesions, offers clinicians an important tool for imaging of a broad range of patients, including those with dense breasts. The MBI localization accessory is a complementary technology to the Discovery NM750b system that is designed to accurately locate, in three dimensions, lesions in the breast using information derived from stereotactic pairs of two-dimensional images. It is intended to provide guidance for interventional purposes such as biopsy and pre-surgical.

For more information: www.dilon.com, www.gehealthcare.com

Related Content

Explaining the Mammography Quality Standards Act
Feature | Mammography | October 16, 2018
The Mammography Quality Standards Act (MQSA) was enacted to improve the quality of mammography and ensure that all...
CORAR Supports Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2018
News | Radiopharmaceuticals and Tracers | October 12, 2018
October 12, 2018 — The Council on Radionuclides and Radiopharmaceuticals Inc.
iCAD Announces Positive Clinical Results for Artificial Intelligence Tomosynthesis Technology
News | Mammography | October 11, 2018
iCAD Inc. announced positive clinical results of its new digital breast tomosynthesis (DBT) cancer detection software,...
Huntsman Cancer Institute Installs First Preclinical nanoScan 3T PET/MRI in U.S.
News | PET-MRI | October 10, 2018
The Center for Quantitative Cancer Imaging at Huntsman Cancer Institute (HCI) at the University of Utah in Salt Lake...
"Where's My Mammogram?" Campaign Helps Women Own Breast Health Records
News | Breast Imaging | October 10, 2018
October 10, 2018 — Mammosphere launched “Where’s My Mammogram?,” a public service campaign to help women obtain copie
DenseBreast-info.org Launches European Expansion
News | Breast Density | October 10, 2018
DenseBreast-info.org (DB-I) announced the launch of its international expansion for European medical providers. The...
X-ray Mammography Adoption to Skyrocket for Breast Cancer Detection
News | Mammography | October 08, 2018
Highly populated countries have traditionally been slow adopters of non-conventional business models, but a new Frost...
Cullman Regional Medical Center

Cullman Regional Medical Center (Alabama) is a 145-bed medical center serving more than 175,000 residents in a six-county area and recognized as one of the region’s finest medical facilities.

Sponsored Content | Case Study | PACS | October 05, 2018
When Cullman Regional Medical Center in Alabama decided to switch from 2-D
Feature | Mammography | October 05, 2018 | By Jeff Zagoudis
“Patient-centered care” is a popular term among those in the healthcare industry in the 21st century. It means the...
Feature | Breast Imaging | October 04, 2018 | By Tracy Accardi
It has been nearly eight years since the world’s first digital breast tomosynthesis (DBT) mammography technology was...